

Trevi Therapeutics to Present at 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases

NEW HAVEN, Conn., Nov. 15, 2021 /PRNewswire/ -- [Trevi Therapeutics, Inc.](#) (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio™ (nalbuphine ER) to treat serious neurologically mediated conditions, today announced that Dr. Bill Forbes, Chief Development Officer, will be presenting at the 5th Annual Dermatology Drug Development Summit for Inflammatory Skin Diseases taking place from November 16-18, 2021 in Boston, MA. Dr. Forbes' presentation on "Nalbuphine ER, an Oral Dual Acting Opioid Being Developed for the Treatment of Pruritus Associated with Prurigo Nodularis" will take place on November 18th at 2 p.m. ET. The presentation will be available to conference attendees.

<div>Dr. Forbes, Chief Development Officer, will present on Nalbuphine ER in Pruritus at Dermatology Drug Development Summit</div>	About Trevi Therapeutics, Inc. Trevi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio to treat serious neurologically mediated conditions. Trevi is conducting a Phase 2b/3 clinical trial of Haduvio for the treatment of chronic pruritus associated with prurigo nodularis (PN) and a Phase 2 trial for chronic cough in patients with idiopathic pulmonary fibrosis (IPF). Trevi is also developing Haduvio for the treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson's disease. These conditions share a common pathophysiology that is mediated through opioid receptors in the central and peripheral nervous systems.
--	---

Founded in 2011, Trevi Therapeutics is headquartered in New Haven, CT.

About Haduvio

Haduvio, an investigational therapy, is an oral extended-release (ER) formulation of nalbuphine. Nalbuphine is a mixed κ -opioid receptor agonist and μ -opioid receptor antagonist that has been approved and marketed as an injectable for pain indications for more than 20 years in the United States and Europe. The κ - and μ -opioid receptors are known to be critical mediators of itch, cough and certain movement disorders. Nalbuphine's mechanism of action may also mitigate the risk of abuse associated with μ -opioid agonists because it antagonizes, or blocks, μ -opioid receptors. Parenteral nalbuphine is not currently classified as a controlled substance by the DEA in the United States and by regulatory authorities in most of Europe. Trevi intends to propose Haduvio as the trade name for nalbuphine ER. Haduvio is an investigational therapy that has been granted Fast Track designation by the FDA for the proposed indication of reduction of moderate to severe pruritus in patients with prurigo nodularis. Its safety and efficacy have not been evaluated by any regulatory authority.

Investor Contact

Katie McManus
Trevi Therapeutics, Inc.
203-304-2499
k.mcmanus@trevitherapeutics.com

Media Contact

Rosalia Scampoli
914-815-1465
rscampoli@marketcompr.com

SOURCE Trevi Therapeutics, Inc.

<https://ir.trevitherapeutics.com/2021-11-15-Trevi-Therapeutics-to-Present-at-5th-Annual-Dermatology-Drug-Development-Summit-for-Inflammatory-Skin-Diseases>